ModifiedColorado Rocky Mountain Health PlansPolicy CS079.T

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Defines medical necessity and investigational determinations for minimally invasive endoscopic and laparoscopic procedures to treat GERD, achalasia, diffuse esophageal spasm, and gastroparesis for Colorado Rocky Mountain Health Plans members (state applicability noted).

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy CodePolicy CS079.T

Change TypeCoverage clarificationCPT codes addedtitle/template update

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document prior conservative therapy failure and objective diagnostic testing when requesting coverage for GES, POEM, pyloroplasty, or Z-POEM.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases' to the current title and template updated.

Coverage rationale clarified that gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis.

Applicable CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added.

Supporting information sections (Description of Services, Clinical Evidence, FDA, References) were updated to reflect current information.

7new CPT codes added

GES, POEM, pyloroplastyKey procedures addressed

83% vs 81.7%POEM 2‑yr success

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

~70%G-POEM 1‑yr success

75%patients improving after GES (case series)

12+Procedure codes listed

Coverage Determinations and Clinical Criteria

GES — Medically necessary (specific indications)

Coverage determinations summarized from policy Coverage Rationale:

GES for gastroparesis: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Refer to the U.S. Food and Drug Administration (FDA) section for labeling and Humanitarian Device Exemption (HDE) information.

Pyloroplasty — Medically necessary (specific indications)

Pyloroplasty: Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Evidence includes systematic reviews and SAGES reports documenting improvement in gastric emptying and symptoms; document prior therapies and rationale.

POEM — Medically necessary (achalasia/diffuse spasm)

POEM for achalasia/DIFFUSE ESOPHAGEAL SPASM: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with achalasia or diffuse esophageal spasm.

Supported by randomized trials demonstrating noninferiority to laparoscopic Heller myotomy (Werner et al.) and guideline endorsements (AGA, SAGES); counsel patients on increased post-procedure reflux risk and ensure appropriate manometric and symptom documentation.

Unproven / Not medically necessary (selected therapies)

Not medically necessary / investigational procedures: Per oral endoscopic myotomy for indications other than achalasia or diffuse esophageal spasm (e.g., Zenker's diverticula), gastric POEM (G-POEM) for gastroparesis, endoscopic therapies for GERD, injection or implantation techniques, and the LINX Reflux Management System are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Specific examples and rationale are provided in the policy; Endoluminal therapy with GERDx™ is investigational and not FDA-approved.

Coverage considerations for advanced minimally invasive procedures

Coverage consideration when ALL of the following are met (where applicable based on condition and procedure):

General prerequisites: Documented diagnosis (gastroparesis, achalasia, or Zenker's diverticulum) confirmed by standard testing and refractory to optimal medical and less invasive therapies; detailed documentation of symptom severity and prior treatments; informed consent acknowledging limited long-term comparative data when applicable; plan for follow-up to assess outcomes.

Derived from guideline recommendations and inclusion criteria used in trials and cohort studies.

GES-specific considerations: GES may be considered for medically refractory diabetic or idiopathic gastroparesis as a HUD-level option; document failure of standard therapies (dietary, prokinetics, antiemetics) and counseling regarding limited long-term comparative data.

Supported by ACG and AGA guidance and observational cohort data (Heckert et al.).

Pyloroplasty-specific considerations: Surgical pyloroplasty may be considered for refractory gastroparesis with variable reported success; document prior therapies and rationale for pyloric intervention, and note potential benefit when combined with fundoplication or GES.

Z-POEM (Zenker's diverticulum)

Evidence summary and comparative findings for Z-POEM versus other endoscopic and surgical approaches

evidence_overview: Meta-analyses and comparative observational studies indicate Z-POEM can be a feasible alternative to flexible endoscopic septotomy (FES), with higher clinical success reported in expert centers, but available studies are retrospective, heterogeneous, and limited in long-term follow-up; further prospective long-term data are needed.

Singh et al. (meta-analysis) and multicenter retrospective cohorts (Al Ghamdi et al.) highlight feasibility but note study limitations.

G-POEM (refractory gastroparesis)

Evidence summary for G-POEM in refractory gastroparesis across systematic reviews, RCTs, and cohort studies

Overall summary: Evidence indicates potential benefit of G-POEM for symptom improvement in many patients with refractory gastroparesis but the quality of evidence is low to very low, with heterogeneous outcome definitions, variable etiologies, predominance of tertiary-center series, and limited long-term randomized data.

Supported by systematic reviews (Mandarino, Mohan, Stojilkovic) and ECRI assessments noting evidence limitations.

Efficacy signals: Systematic reviews report approximately 70% 1-year clinical success and pooled before-after improvements in symptom scores and gastric emptying in multiple meta-analyses; small RCTs (Martinek et al.) show benefit versus sham at short-term follow-up.

Mandarino et al. and the Martinek RCT provide these efficacy signals.

Safety and harms: Adverse events reported include bleeding, mucosal injury, peripyloric abscess, dumping syndrome, and rare serious adverse events; small RCT reported three SAEs related to G-POEM.

Martinek et al. and multicenter series (Baret et al.) document these safety findings.

Stretta (radiofrequency for GERD)

Evidence summary for endoscopic radiofrequency (Stretta) in GERD

Overall summary: Available evidence for Stretta is low quality and inconsistent; some studies suggest symptom improvement and reduced PPI use, but randomized sham-controlled trials show no significant benefit and systematic assessments characterize the benefit as potential but unproven.

Hayes, Zerbib RCT, and ECRI assessments summarize conflicting findings and low-quality evidence.

Conflicting results: A 2020 randomized double-blind sham-controlled trial (Zerbib et al.) found no significant difference versus sham on symptom days or PPI use at 24 and 48 weeks, whereas uncontrolled series report symptomatic improvement up to longer-term follow-up.

Zerbib (2020) contrasted with earlier smaller crossover and cohort studies (Arts et al., case series).

Evidence quality: Systematic reviews and technology assessments note small sample sizes, heterogeneity, and high risk of bias, and call for large multicenter RCTs to establish comparative effectiveness versus fundoplication and other endoscopic techniques.

ECRI and Hayes assessments document these limitations.

Typical trial-based eligibility themes

Trials and systematic reviews generally enrolled patients meeting ALL of the following:

Typical eligibility themes: 1) Chronic GERD symptoms despite adequate PPI therapy or PPI dependence; 2) Objective evidence of pathologic reflux (ambulatory pH monitoring, DeMeester score) or supportive endoscopic findings; 3) Anatomic suitability for the device/procedure (e.g., limited hiatal hernia size as specified in trials); 4) Patient preference to avoid lifelong PPI therapy or fundoplication; 5) Informed consent acknowledging limited long-term durability evidence and potential need for subsequent surgery.

These themes reflect inclusion criteria used across TIF, MSA, Stretta and other trials and are not standalone payer rules.

TIF (EsophyX) coverage considerations

Evidence shows short- to mid-term symptom improvement but limitations exist; consider coverage when ALL criteria met:

TIF candidate criteria: Patient has chronic GERD symptoms refractory to optimized medical therapy (PPI use) AND meets device-specific anatomic criteria used in trials (for example, small or absent hiatal hernia in many EsophyX studies) AND documentation of objective testing where available (abnormal pH or other objective reflux testing) AND informed consent acknowledging limited long-term durability evidence.

Trials often excluded large hiatal hernias and severe esophagitis; durability beyond 5 years is variably reported.

LINX / Magnetic sphincter augmentation coverage considerations

MSA shows promising short-term efficacy and high rates of PPI discontinuation but long-term safety (erosion, explantation) and comparative effectiveness evidence remain limited. Coverage when ALL of the following are met:

MSA candidate criteria: Patient with PPI-refractory GERD or inadequate symptom control on PPIs AND objective confirmation of pathologic reflux (pH testing) AND anatomic suitability (hiatal hernia size within studied limits) AND patient counseling regarding risks including postoperative dysphagia, need for dilation, and potential device removal/explantation.

RCTs and systematic reviews report high rates of PPI discontinuation and improved HRQL but note postoperative dysphagia and device removal/erosion risks; device is FDA PMA-cleared (PMA P100049) and selection should align with guideline recommendations.

Polymer injection/implantation (Durasphere, Plexiglas) stance

Available evidence is insufficient to establish safety and efficacy.

Polymer injection: Techniques using injectable bulking agents or implanted polymers (e.g., Durasphere, Plexiglas) for GERD are considered experimental/unproven and not medically necessary due to limited and low-quality evidence and lack of long-term safety and efficacy data.

Systematic reviews and small case series report short-term reductions in PPI use but lack robust comparative trials.

Covered with conditions (evidence- and guideline-informed)

Coverage consideration statements and evidence summaries from RCTs and society guidelines:

MSA consideration: Patient selection should follow guideline recommendations: objective evidence of GERD with persistent regurgitation or inadequate symptom control despite optimized PPI therapy, and candidacy for an anti-reflux procedure; consider MSA as an alternative to fundoplication per ACG/ASGE/SAGES guidance.as per guideline-recommended testing and anatomic criteria

Guidelines (ACG, ASGE, SAGES) and RCTs (Bell et al.) support MSA in selected patients but advise shared decision-making regarding risks and long-term data.

Device safety/effectiveness evidence: Evidence includes RCTs, systematic reviews, and cohort studies showing reduced regurgitation, improved GERD-HRQL, and high rates of PPI cessation in many patients, with procedure-specific risks (dysphagia, need for dilation, explantation, rare erosion).see reported rates in cited studies

Reported transient dysphagia ~10% at 1 year with decline over time; device removal/explantation and rare erosion have been reported in cohort series and registries.

Updated coverage rationale and state applicability

Policy updates and applicability notes

Title and applicability: Policy title and state-specific references were updated; language pertaining to Louisiana was removed and state-specific policy links were refreshed for applicable states.

See Policy History/Revision Information for details.

GES coverage rationale update: Policy states GES therapy is proven and medically necessary for treating refractory gastroparesis; full coverage criteria and FDA/HDE details are included in the main policy body.

This extract indicates an added clarification to the Coverage Rationale; refer to the full policy for complete operational criteria and FDA labeling details.

Endoluminal therapy using the GERDx™ device is considered investigational and not medically necessary for treatment of gastroesophageal reflux disease (GERD). The policy explicitly states GERDx™ has not received FDA approval for this indication and therefore is classified as unproven for routine coverage.

Reference documentation describes GERDx™ as an endoscopic full‑thickness plication device evaluated in limited series; because regulatory clearance and robust comparative evidence are lacking, GERDx™ remains investigational per the Coverage Rationale.

Procedures performed without documentation of prior adequate conservative or medical therapy failure, without objective diagnostic confirmation of disease, or without documented informed consent about uncertain long‑term outcomes are not supported by this policy. Trials and reviews repeatedly required prior PPI optimization or documented refractory symptoms before considering endoluminal or advanced interventions.

Endoscopic plication/suturing and other investigational approaches have been limited by small, nonrandomized studies and variable preprocedure selection (including incomplete PPI trial documentation), so absence of prior standard therapy or diagnostic confirmation undermines candidacy for coverage.

Endoscopic therapies for GERD, including radiofrequency ablation (Stretta) and other endoluminal techniques, are described in the policy as unproven due to insufficient and low‑quality evidence of sustained efficacy and durability.

Systematic reviews, technology assessments, and randomized trials cited in the policy show inconsistent results, small sample sizes, and methodological limitations that preclude routine coverage of these endoscopic GERD therapies as established alternatives to medical therapy or surgical fundoplication.

Patients who lack objective improvement on appropriate diagnostic testing (for example, persistent abnormal pH metrics or absent symptomatic response on validated scores), or whose anatomy exceeds device limits (such as a larger hiatal hernia than allowed in trial inclusion), are considered unsuitable for coverage for many endoluminal GERD procedures.

Studies of endoscopic plication and transoral fundoplication commonly excluded patients with large hiatal hernias or severe esophagitis, and long‑term analyses report progressive loss of benefit in some cohorts; these considerations support excluding patients without documented objective improvement or anatomic suitability.

Endoluminal and endoscopic procedures such as TIF and other device‑based fundoplication approaches should not be considered equivalent to laparoscopic Nissen fundoplication (LNF) for long‑term physiologic control of GERD. Network meta‑analysis and systematic reviews indicate LNF achieves superior physiologic improvements (LES pressure, acid exposure) while TIF and similar techniques have shorter follow‑up and variable durability.

Because long‑term comparative data are limited and heterogeneous, these endoscopic interventions cannot be assumed to provide durable physiologic control comparable to LNF for coverage purposes.

The Enterra gastric electrical stimulation (GES) system has FDA Humanitarian Device Exemption (HDE) labeling that specifies contraindications. Per the FDA label, the device should not be used in patients with gastric obstruction or pseudo‑obstruction, prior gastric resection, prior fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

Use of Enterra outside these labeled contraindications or outside the HDE indications (chronic intractable drug‑refractory nausea and vomiting secondary to diabetic or idiopathic gastroparesis) may be excluded from coverage.

Language and content that specifically referenced the state of Louisiana have been removed from the policy. The policy revision notes a title and template update and clarifies state‑specific applicability; reviewers should refer to the applicable state‑specific policy version for local criteria.

Operational changes in the revision history indicate removal of Louisiana‑specific wording rather than changes to the clinical coverage determinations themselves.

The policy summarizes the range of endoscopic therapies and devices considered in the document, including Stretta (radiofrequency), endoscopic plication/suturing systems (e.g., NDO Plicator, GERDx™), MUSE™, EsophyX™ (TIF), polymer injection/implantation techniques (Plexiglas, Durasphere), and the LINX (magnetic sphincter augmentation) system.

Descriptions and device mechanisms are provided in the policy’s Description of Services and supporting evidence sections; these technologies are evaluated individually for regulatory status and quality of evidence to inform coverage determinations.

Interventions lacking comparative evidence of durable benefit or performed for indications not supported by cited guidance and studies are identified as not medically necessary or investigational. Examples include polymer injection/implantation techniques and other bulking or implantable materials that have limited, small‑sample evidence and inadequate long‑term safety or effectiveness data.

The policy highlights that many endoscopic approaches suffer from short follow‑up, inconsistent outcome measures, and lack of randomized comparative data—limitations that underlie noncoverage determinations for several procedures.

The policy emphasizes that G‑POEM remains investigational for routine practice: while pooled observational data and some trials indicate a symptomatic benefit (with reported ~70% 1‑year success in some meta‑analyses), the overall evidence quality is low and durability and generalizability are uncertain.

Consequently, routine coverage of G‑POEM is not supported; case selection, prospective data collection, and further randomized comparative studies are needed to clarify the role of G‑POEM.

Endoscopic plication and suturing approaches have insufficient evidence to support sustained long‑term benefit. The policy cites long‑term follow‑up studies showing symptomatic improvement early after treatment but progressive loss of effect over time and lack of improvement in objective testing (pH/manometry) in some series.

Given the absence of high‑quality randomized trials with durable outcomes, these techniques are not endorsed as equivalent to surgical fundoplication for durable reflux control.

Polymer injection/implantation techniques are explicitly considered not medically necessary in this policy because the available evidence is limited, drawn largely from small case series and older studies, and does not adequately demonstrate long‑term safety or efficacy.

The policy notes that although some small cohorts reported reductions in medication use short‑term, the lack of controlled, durable outcome data prevents recommending these techniques for routine coverage.

ACG guideline recommendations and cited randomized trials inform the policy’s stance on Stretta: the ACG guidance advises against routine use of radiofrequency energy for GERD because of inconsistent outcome data and low quality of evidence.

The policy aligns with these guideline conclusions, describing Stretta as an intervention with inconsistent efficacy and thus not recommended for routine coverage.

Before applying this policy, verify the member’s federal, state, and contractual benefit terms. The policy explicitly states that in case of conflict, the federal, state, or contractual requirements for benefit coverage govern the final determination.

Plan‑level prior authorization rules, state mandates, or contractual exclusions may supersede the standard policy recommendations and should be reviewed prior to coverage decisions.

Applicable Procedure and Device Codes

Applicable CPT Codes (reference)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.

1–10 of 14

1/2

EsophyX TIF (procedure codes not listed in this section)mixed

CPT/HCPCS not specified

EsophyX TIF procedures (device-based transoral fundoplication) — clinical studies summarized; specific billing codes are not enumerated in this section.

LINX MSA (procedure codes not listed in this section)mixed

CPT/HCPCS not specified

LINX / magnetic sphincter augmentation procedures — clinical literature summarized; billing codes are not provided in this excerpt. FDA PMA identifier P100049 is cited in the FDA section.

Polymer injection/implantation (codes not listed)mixed

CPT/HCPCS not specified

Polymer injection/implantation techniques (e.g., Plexiglas, Durasphere) — evidence summarized; specific billing codes are not listed in this section.

Regulatory / Device identifiersmixed

P100049

FDA PMA number for the LINX Reflux Management System.

Applicable CPT Codes (added)CPT

43647	CPT code added (description in main policy)
43648	CPT code added (description in main policy)
43659	CPT code added (description in main policy)
43881	CPT code added (description in main policy)
43882	CPT code added (description in main policy)
64590	CPT code added (description in main policy)
64595	CPT code added (description in main policy)

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for interventions described in this policy. Verify member benefits and obtain prior authorization before scheduling procedures to avoid claim denials.

Prior authorization may be required for GES (Enterra), G-POEM, POEM, surgical pyloroplasty, LINX (MSA), TIF/EsophyX, and other endoscopic anti-reflux procedures.
Provide clinical documentation supporting medical necessity: history of refractory symptoms, failed conservative/medical therapy (including PPI trial for GERD when applicable), results of objective testing (e.g., gastric emptying study for gastroparesis; pH testing, manometry, endoscopy for GERD), and prior treatments attempted.

Documentation Required

Documentation Required for Review

Document and submit complete medical records relevant to the request. Medical records may be requested to assess whether the member meets clinical criteria and do not guarantee coverage.

Clinical Definitions and Procedure Glossary

Achalasia definition

DefinitionA primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus resulting in impaired relaxation of the esophagogastric junction and loss of organized peristalsis in the esophageal body.

Typical diagnostic confirmationManometry demonstrating impaired EGJ relaxation and absent peristalsis; timed barium esophagram or endoscopy often used for supporting evaluation.

Common clinical featuresProgressive dysphagia to solids and liquids, regurgitation, and chest pain; Eckardt score used in trials to assess severity and response.

Diffuse Esophageal Spasm definition

DefinitionA rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude, commonly accompanied by dysphagia.

Clinical features

Clinical and Evidence Background

Background: Gastroesophageal reflux disease (GERD) results from dysfunction of the lower esophageal sphincter and may lead to esophagitis, strictures, Barrett’s esophagus, or esophageal adenocarcinoma. Gastroparesis is characterized by delayed gastric emptying with symptoms including nausea, vomiting, early satiety, and requires objective evidence such as gastric emptying scintigraphy for diagnosis.

This policy addresses minimally invasive endoscopic and laparoscopic procedures for GERD, achalasia, diffuse esophageal spasm, and gastroparesis and defines which interventions are considered proven, investigational, or not medically necessary based on current evidence and regulatory status.

Policy Revision History

2026-06-01state_policy_update

Updated reference link for Idaho state-specific policy version; administrative alignment with current title.

2026-05-01state_policy_update

Updated reference link for North Carolina state-specific policy version to reflect the current title.

2026-04-01title_and_substantive_revisionLatest

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy CodePolicy CS079.T

Change TypeCoverage clarificationCPT codes addedtitle/template update

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document prior conservative therapy failure and objective diagnostic testing when requesting coverage for GES, POEM, pyloroplasty, or Z-POEM.

SourceLink

On This Page

Supported by systematic reviews reporting variable success rates (Fonseca; Zoll) and SAGES guidance.

POEM-specific considerations: POEM is an effective option for achalasia (types I–III) supported by randomized data; ensure appropriate manometry, timed barium or Eckardt score documentation and counsel on higher reflux risk post-procedure.

Based on Werner RCT and AGA/SAGES recommendations.

Z-POEM-specific considerations: Z-POEM may be considered as an emerging alternative to flexible or rigid septotomy for Zenker's diverticulum in selected patients when documented rationale and informed consent about limited long-term comparative data are provided.

Evidence from meta-analyses and retrospective cohorts suggests comparable short-term success but limited long-term data (Singh et al.; Al Ghamdi et al.).

Evidence gaps: Lack of large multicenter RCTs, inconsistent outcome definitions, variable follow-up, and uncertain durability limit strong coverage recommendations; further comparative trials versus surgical pyloromyotomy or sham are needed.

ECRI assessment and systematic reviews emphasize the need for higher-quality evidence.

Include symptom severity scores (e.g., GCSI, GERD-HRQL, Eckardt score) when available.

Include results of diagnostic testing: 4-hour gastric emptying scintigraphy for gastroparesis, esophageal pH monitoring/DeMeester score, manometry, and endoscopy findings for GERD/achalasia evaluation.

Step Therapy

Step Therapy / Treatment Sequencing

Step therapy and sequencing of treatments are expected prior to approval of invasive procedures in many cases.

For gastroparesis: trial of optimized medical therapy (dietary modification, prokinetic agents, antiemetics) and consideration of pyloric-targeted therapies before device implantation when clinically appropriate.
For GERD: adequate trial of once- or twice-daily PPI therapy and objective evidence of reflux (pH testing, endoscopic findings) prior to consideration of endoscopic or surgical anti-reflux procedures (including MSA/LINX and TIF).

Denial Risk

Denial Risk — Insufficient Evidence

There is an evidence insufficiency and potential denial risk for procedures judged unproven by this policy.

G-POEM is considered unproven for gastroparesis by this policy and may be denied without compelling supportive documentation of durable benefit.
Endoscopic anti-reflux therapies listed as unproven (including certain plication/suturing techniques, Stretta RF in some contexts, and investigational devices) are at higher risk for denial without strong evidence and FDA approval where applicable.

Billing Rule

Coding and Billing Note

Coding and billing guidance: include applicable CPT codes on authorization and claims; listing of codes is for reference and does not imply coverage. Verify correct CPT for the performed procedure and any device-specific codes.

Covered/ referenced CPTs include: 43210, 43257, 43284, 43289, 43497, 43499, 43647, 43648, 43659, 43881, 43882, 43999, 64590, 64595.
Use unlisted code reporting (e.g., 43289, 43499, 43659, 43999) when procedures lack a specific CPT; provide operative report and documentation to support coding and medical necessity.

Note

Provider Action Checklist

Provider actions to support favorable review: obtain prior authorization, submit complete clinical records and objective diagnostic testing, document prior conservative therapies and rationale for procedural selection.

Include device-specific contraindications from FDA labeling when relevant (e.g., Enterra contraindications) and address them in the clinical record.
Verify member benefit coverage terms and any state or contract-specific requirements prior to authorization.
When submitting requests for MSA/LINX or TIF, include prior PPI trial details, hiatal hernia size, DeMeester score or pH results, and endoscopic findings to demonstrate candidacy.

Intermittent chest pain, dysphagia, and episodic solid/liquid swallowing difficulty; diagnosis supported by manometry showing spasm patterns.

ContextDistinguished from achalasia by preserved peristaltic amplitude but disordered propagation; considered in differential of nonobstructive dysphagia.

Gastroesophageal Reflux Disease (GERD) definition

DefinitionA condition in which the lower esophageal sphincter relaxes too often or weakens, allowing stomach acid to reflux into the esophagus.

Clinical consequencesCan cause esophagitis, strictures, Barrett's esophagus, and increased risk of adenocarcinoma if chronic and untreated.

Typical evaluationDiagnosis supported by endoscopy and objective reflux testing (ambulatory pH or impedance monitoring); trials require objective confirmation in many studies.

Gastroparesis definition

DefinitionA digestive disorder in which gastric motility is abnormal or absent, also known as delayed gastric emptying.

SymptomsNausea, vomiting, early satiety, bloating, and postprandial fullness; severity often measured with GCSI or PAGI-SYM in studies.

Objective confirmationDiagnosis requires objective evidence of delayed gastric emptying (scintigraphic gastric emptying study is reference standard).

GES definition

DefinitionGastric Electrical Stimulation (GES) — implantable Enterra Therapy System that delivers electrical stimulation to reduce symptoms of refractory gastroparesis (chronic intractable nausea and vomiting).

Regulatory noteEnterra has an FDA Humanitarian Device Exemption (HDE) for chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis in adults aged 18–70 years.

Label contraindicationsPer FDA labeling, Enterra should not be used in patients with gastric obstruction/pseudo-obstruction, prior gastric resection or fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

POEM definition

DefinitionPer Oral Endoscopic Myotomy (POEM) — an endoscopic myotomy technique for achalasia that creates a submucosal tunnel and performs esophageal muscle division to relieve outflow obstruction.

Evidence contextRandomized trials (Werner et al.) demonstrated POEM is noninferior to laparoscopic Heller myotomy for achalasia with similar 2‑year clinical success but higher post-procedure reflux risk.

Guideline positionAGA and ASGE recognize POEM as an effective therapy (preferred for type III achalasia per AGA) and recommend performance by experienced operators in high-volume centers.

Z-POEM definition (brief)

DefinitionZ-POEM (Zenker's peroral endoscopic myotomy) — an endoscopic myotomy technique applied to Zenker's diverticulum to divide the party wall/septum endoscopically.

Evidence summaryComparative observational studies and a recent meta-analysis suggest Z-POEM can be a feasible alternative to flexible endoscopic septotomy with comparable short-term clinical success, but long-term comparative data are limited and quality is low.

Clinical caveatMost supporting data are retrospective, single- or multi-center cohorts; prospective long-term studies are needed to define durability and recurrence risk.

Z-POEM alternate entry

Alternate entryZenker's peroral endoscopic myotomy (Z-POEM) — endoscopic septotomy approach for Zenker's diverticulum with reported high initial clinical success but limited long-term comparative evidence.

Key evidenceMeta-analysis (Singh et al., 2025) and multi-center retrospective cohorts report similar or higher short-term success versus flexible endoscopic septotomy but note heterogeneity and retrospective designs.

RecommendationConsidered emerging; informed consent should include uncertainty about long-term outcomes and potential need for reintervention.

G-POEM definition

DefinitionG-POEM (gastric peroral endoscopic myotomy) — an endoscopic pyloric-directed myotomy intended to improve gastric emptying for refractory gastroparesis.

Evidence contextSystematic reviews and cohort studies report symptomatic improvement in many patients (approximately ~70% 1‑year clinical success reported in some reviews) but overall evidence quality is low and heterogeneous.

Clinical considerationsG-POEM is technically successful in experienced centers, but limited randomized long-term data and variable outcome definitions limit broad routine coverage; prior medical/conservative therapy failure and objective delayed gastric emptying are key selection features in trials.

Stretta definition

DefinitionStretta — endoscopic radiofrequency energy system delivering thermal energy to the gastroesophageal junction aiming to reduce GEJ compliance and improve GERD symptoms.

Evidence statusSystematic reviews and technology assessments report low-quality, inconsistent evidence; randomized sham-controlled trials (e.g., Zerbib 2020) found no significant benefit versus sham in key outcomes.

Clinical implicationConsidered a potential but unproven option; guidelines (ACG) do not recommend routine use due to inconsistent efficacy data.

Stretta alternate definition

Alternate definitionEndoscopic radiofrequency (Stretta) — RF needles deliver energy to muscle at the GEJ; some observational studies report symptom and PPI-use improvements but well‑conducted RCTs show inconsistent benefit.

Key trialZerbib et al. (2020) randomized double‑blind sham‑controlled trial (n=62) found no significant difference between Stretta and sham for days without heartburn, PPI use, or other symptoms at 24 and 48 weeks.

Evidence gapMeta-analyses limited by small samples, heterogeneous designs, and lack of long-term comparative data; larger RCTs needed.

TIF / EsophyX definition

DefinitionTIF / EsophyX — transoral incisionless fundoplication using the EsophyX system to create an endoluminal fundoplication (gastroesophageal valve) to reduce reflux.

Evidence summarySystematic reviews (McCarty et al., Hayes, ECRI) report short-to‑mid‑term symptom and quality-of-life improvements, but overall evidence quality is low and long-term comparative data versus laparoscopic fundoplication are limited.

Typical trial populationTrials often enrolled patients with chronic PPI-dependent or refractory GERD and limited hiatal hernia size; objective testing was variably reported.

EFTP / endoscopic full-thickness plication definition

DefinitionEFTP / endoscopic full-thickness plication — endoscopic device‑mediated suturing/plication creating full‑thickness cardia plications to treat GERD.

Evidence highlightsRandomized and prospective trials report symptom improvement and reduced PPI use (e.g., Kalapala et al. 2022; Rothstein et al. 2006), but durability and long-term comparative effectiveness remain uncertain.

Clinical notePromising short-term results in some RCTs; further larger and longer‑term trials needed to establish durability.

MUSE definition

DefinitionMUSE — Medigus Ultrasonic Surgical Endostapler, a transoral stapling device used to create an anterior partial fundoplication for treatment of chronic GERD.

Regulatory noteMUSE received 510(k) clearance for endoluminal stapling to create partial fundoplication in selected patients responding to pharmacologic therapy.

Evidence summaryProspective case series report symptom and PPI-use improvement in many patients but small sample sizes and procedure-related severe adverse events have been reported; long-term comparative data are limited.

TIF (Transoral Incisionless Fundoplication) definition

DefinitionTIF (Transoral Incisionless Fundoplication) — endoluminal fundoplication performed with devices such as EsophyX to create plications at the gastroesophageal junction and reduce reflux symptoms.

Evidence contextMeta-analyses and systematic reviews report high technical success and symptomatic benefit in many series but emphasize heterogeneous study designs and limited direct comparisons to laparoscopic Nissen fundoplication.

Clinical limitationMany trials excluded large hiatal hernias and severe esophagitis; patient selection and counseling on durability are important.

MSA / LINX definition

DefinitionMagnetic Sphincter Augmentation (MSA) / LINX — laparoscopically implanted ring of magnetic beads placed around the lower esophageal sphincter to augment sphincter function and reduce reflux.

Regulatory statusLINX received FDA premarket approval (PMA P100049); device-specific prior authorization may be required.

Evidence and risksSystematic reviews and RCTs report short-term efficacy and high rates of PPI discontinuation, but concerns remain about long-term safety (dysphagia, device removal, rare erosion) and comparative durability versus fundoplication.

Polymer injection/implantation definition

DefinitionPolymer injection/implantation — endoscopic bulking agent injections or implantation (e.g., Plexiglas [PMMA], Durasphere) intended to increase LES resistance to reflux.

Evidence stanceAvailable evidence is insufficient to establish safety and efficacy; systematic reviews and small case series show mixed results and inadequate long-term data.

Regulatory noteSome injectable bulking agents have FDA approvals for other indications, but clinical use for GERD lacks robust evidence and is considered investigational in many reviews.

MSA (LINX) alternate entry

Alternate entryMSA (LINX) — FDA‑approved magnetic sphincter augmentation system (PMA P100049) that augments the LES with a ring of magnetic beads; shows promising short-term outcomes but requires counseling on dysphagia and potential device removal.

Evidence summaryReviews and RCTs report improved GERD‑HRQL and high rates of PPI cessation; long‑term comparative effectiveness and rare device‑related complications remain areas of uncertainty.

Coverage implicationMSA may be considered when patients have objective evidence of GERD, are PPI‑refractory or dependent, and meet anatomic and clinical selection criteria used in trials.

TIF alternate definition

Alternate definitionTIF — endoluminal fundoplication performed transorally (EsophyX/MUSE) to create plications at the gastroesophageal junction; shown to improve symptoms and reduce PPI use in many observational studies and some RCTs but long‑term comparative evidence is limited.

Key evidenceSystematic reviews (McCarty et al., Hayes, ECRI) summarize multiple RCTs and cohort studies with variable follow-up and emphasize need for longer controlled trials.

Patient selectionTrials commonly enrolled patients with PPI‑refractory symptoms, limited hiatal hernia size, and objective or symptomatic confirmation of GERD; counseling on limited long‑term durability is advised.

G-POEM alternate definition

Alternate definitionG-POEM — endoscopic pyloromyotomy for refractory gastroparesis; technique aims to improve gastric emptying by dividing pyloric muscle via submucosal tunneling.

Evidence summarySystematic reviews and some randomized data report symptomatic improvement in many patients but highlight low to very low quality evidence, heterogeneity, and limited long‑term RCT data.

Clinical selectionTrials typically required objective delayed gastric emptying and failure of medical/conservative therapies; procedure best performed by experienced endoscopists in specialized centers.

Gastroparesis definition updated

Updated definitionGastroparesis — policy updated the definition wording; overall defined as delayed gastric emptying with abnormal or absent gastric motility (delayed gastric emptying).

Policy change noteDefinitions section updated in the 04/01/2026 revision (title change and supporting information updates noted in policy history).

Clinical implicationObjective confirmation of delayed gastric emptying (e.g., gastric emptying scintigraphy) remains a key requirement for diagnosing gastroparesis in coverage considerations.

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases'; template updated and content referencing Louisiana removed; coverage rationale clarified to state gastric electrical stimulation (GES) therapy is proven and medically necessary for specified indications and CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added to Applicable Codes.